Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02574962 |
Recruitment Status :
Withdrawn
First Posted : October 14, 2015
Last Update Posted : July 18, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Inflammatory Demyelinating Polyneuropathy | Drug: H.P. Acthar® Gel | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy |
Study Start Date : | August 2015 |
Estimated Primary Completion Date : | July 2018 |
Estimated Study Completion Date : | July 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Acthar® Gel
For the first two weeks participants will receive 1 mL of study drug subcutaneously every other day. After that, participants will received 1 mL of study drug twice a week for up to 6 months.
|
Drug: H.P. Acthar® Gel
Other Names:
|
- Number of Participants With Treatment-Related Adverse Events [ Time Frame: 28 Weeks ]Count of adverse events experienced by study participants.
- Efficacy of study drug [ Time Frame: Change from Baseline to 28 Weeks ]Measured using the Inflammatory Neuropathy Cause and Treatment (INCAT) score. The INCAT scale has upper and lower extremity components (maximum of 5 points for upper (arm disability) and maximum of 5 points for lower (leg disability) that add up to a maximum of 10-points. A score of 0 indicates no problems. A score of 10 indicates person is severely incapacitated.
- Maximum Grip Strength [ Time Frame: 28 weeks ]Measured by the amount of force a person uses to squeeze around a dynamometer.
- Manual Muscle Testing (MMT) [ Time Frame: 28 Weeks ]Measure based on the Medical Research Council (MRC) sum score (strength score combined for 12 specified muscle groups) on MMT.
- Rasch-built Overall Disability Scale (R-ODS) [ Time Frame: 28 Weeks ]The R-ODS is a questionnaire that rates a person's ability to perform 24 daily activities such as eating, using the toilet, taking a shower, dressing, walking, dancing, running, or standing. Scores range from 0-48 with 0 meaning they cannot perform any of the tasks and 48 meaning they can perform all of the tasks without any difficulty.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- CIDP diagnosed according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria 2010
- Age > 18 years
- Able to give written informed consent
- Patient's signs and symptoms should not be better explained by another disease process
- Patients can be on prednisone as long as there has been no dose change for 4 weeks from baseline
- Patients can be on following drugs as long as there has been no change for 60 days from baseline visit including azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, intravenous immunoglobulin (IVIg) or other immunosuppressive drugs
- INCAT score greater than or equal to 2
Exclusion Criteria:
- Presence of any other causes of polyneuropathy or multifocal motor neuropathy, which in the opinion of the investigator is the major contributor to the numbness and weakness.
- Other neurologic or orthopedic condition causing weakness
- Treatment with plasma exchange (PLEX) within the last 30 days from baseline
- Participation in another trial within the last 30 days from baseline or two ½ life of the drug being studied.
- Latent tuberculosis or active infection
- Contraindication per Acthar® Gel prescribing information scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history or presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, or adrenal cortical hyperfunction.
- History of prior sensitivity to Acthar® Gel or other porcine products
- Previous or present Infection with hepatitis C and hepatitis B
- Pregnancy or nursing mothers.
- Female subjects of childbearing potential either not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study, or not sexually abstinent for the entire duration of the study, or not surgically sterile.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02574962
United States, Arizona | |
Phoenix Neurological Associates | |
Phoenix, Arizona, United States, 85018 | |
United States, California | |
University of Southern California | |
Los Angeles, California, United States, 90033 | |
United States, Kansas | |
University of Kansas Medical Center | |
Kansas City, Kansas, United States, 66160 | |
United States, Tennessee | |
Wesley Neurology Group | |
Memphis, Tennessee, United States, 38163 | |
United States, Vermont | |
University of Vermont | |
Burlington, Vermont, United States, 05405 |
Principal Investigator: | Mamatha Pasnoor, MD | University of Kansas Medical Center |
Responsible Party: | Mamatha Pasnoor, MD, Associate Professor, University of Kansas Medical Center |
ClinicalTrials.gov Identifier: | NCT02574962 |
Other Study ID Numbers: |
STUDY00002770 |
First Posted: | October 14, 2015 Key Record Dates |
Last Update Posted: | July 18, 2016 |
Last Verified: | July 2016 |
Polyneuropathies Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases Polyradiculoneuropathy Autoimmune Diseases of the Nervous System |
Demyelinating Diseases Autoimmune Diseases Immune System Diseases Adrenocorticotropic Hormone Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |